Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia. XWPharma to receive $20 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales
Article Date
September 3, 2025
This article is featured on another website.
Go to article
September 1, 2026
HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
HiRO and Differentia have signed a Memorandum of Understanding establishing a framework for joint development…
September 1, 2026
HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
HiRO and Differentia have signed a Memorandum of Understanding establishing a framework for joint development…
June 5, 2026
Brain Tumors – Still an Area of Significant Unmet Need
The Challenge of Brain Tumors Brain tumors remain a serious challenge due to their complex…
June 5, 2026
Brain Tumors – Still an Area of Significant Unmet Need
The Challenge of Brain Tumors Brain tumors remain a serious challenge due to their complex…